ViewPoint Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 11

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $61.4K

  • Investors
  • 14

ViewPoint Therapeutics General Information

Description

Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, enabling physicians to have drugs that prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States
+1 (734) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ViewPoint Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 08-Nov-2019 $61.4K 0000 Completed Generating Revenue
5. Early Stage VC (Series B) 05-Mar-2018 0000 0000 0000 Completed Generating Revenue
4. Early Stage VC (Series A) 02-May-2016 00.000 00.000 000.00 Completed Generating Revenue
3. Grant 01-Apr-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator 06-Oct-2014 Completed Generating Revenue
To view ViewPoint Therapeutics’s complete valuation and funding history, request access »

ViewPoint Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view ViewPoint Therapeutics’s complete cap table history, request access »

ViewPoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin sta
Drug Discovery
San Francisco, CA
11 As of 2020
0000
0000000000 0 0000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, q
0000 000000000
San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mo
0000 000000000
Boston, MA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViewPoint Therapeutics Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Escape Bio Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
00000000000 Venture Capital-Backed Boston, MA 00 00000 00000000000 00000
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
You’re viewing 5 of 26 competitors. Get the full list »

ViewPoint Therapeutics Patents

ViewPoint Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3347368-A4 Compounds and formulations for treating ophthalmic diseases Withdrawn 08-Sep-2015 0000000000 0
JP-2018526423-A Compounds and formulations for treating ophthalmic diseases Pending 08-Sep-2015 0000000000
EP-3347368-A1 Compounds and formulations for treating ophthalmic diseases Withdrawn 08-Sep-2015 0000000000
US-20180250313-A1 Compounds and formulations for treating ophthalmic diseases Abandoned 08-Sep-2015 0000000000
AU-2016321254-A1 Compounds and formulations for treating ophthalmic diseases Abandoned 08-Sep-2015 A61K31/575
To view ViewPoint Therapeutics’s complete patent history, request access »

ViewPoint Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Noelynn Oliver Senior Director, Biology
You’re viewing 1 of 8 executive team members. Get the full list »

ViewPoint Therapeutics Board Members (7)

Name Representing Role Since
Edward Hurwitz Self Chairman 000 0000
Emmett Cunningham Ph.D ViewPoint Therapeutics Board Member 000 0000
Heath Lukatch Ph.D TPG Board Member 000 0000
Peter Moldt Ph.D Novo Holdings Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

ViewPoint Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViewPoint Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Novo Holdings Venture Capital Minority 000 0000 000000 0
The Rise Fund Impact Investing Minority 000 0000 000000 0
TPG PE/Buyout Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »